Gilbert M, Ellis C N, Voorhees J J
Dermatologica. 1986;172(3):160-3. doi: 10.1159/000249322.
We prospectively analyzed radiographic skeletal surveys of eight patients who received etretinate therapy for psoriasis at doses ranging from 0.5 to 1.2 mg/kg/day for 6-18 months. Although subtle skeletal changes could have been obscured by some of our patients' other radiographic abnormalities, no bony changes that could be attributed to etretinate were detected in any of these patients.
我们前瞻性地分析了8例接受依曲替酯治疗银屑病患者的骨骼X线检查结果，这些患者的用药剂量为0.5至1.2mg/kg/天，疗程为6至18个月。尽管我们部分患者的其他X线异常可能掩盖了细微的骨骼变化，但在这些患者中均未检测到可归因于依曲替酯的骨质改变。
